Trial · NCT03186378
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
NCT03186378, Phase 2, Completed, Verrica Pharmaceuticals Inc.; results first posted 2021-08-09
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. Trials, record NCT03186378. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03186378
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
- NCT number
- NCT03186378
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 33 participants, actual
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Conditions
- Molluscum Contagiosum
- Interventions
- VP-102 with applicator
- First posted
- 2017-06-14
- Last updated
- 2021-08-11
- Results first posted
- 2021-08-09
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | 24 hours | The primary objective is to determine any potential systemic exposure from a single 24-hour dermal application of VP-102 topical film-forming solution when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older. |
| Secondary | Measurement of Efficacy - Complete Clearance | Baseline through EOS Day 84 | Proportion of subjects exhibiting complete clearance of all treated molluscum lesions (baseline and new) on or before Week 12 (EOS). |
| Other | Proportion of Subjects Exhibiting a 90% or Greater Reduction of All Treated Molluscum Lesions (Baseline and New) at the EOS Visit. | Baseline to EOS Day 84 | Summaries of \>=90% clearance by visit include clearance at that visit or any earlier visit (cumulative) baseline and ew at the EOS visit. |
| Other | Percent Reduction of Treated Molluscum Lesions From Baseline at the EOS Visit. | Baseline to EOS Day 84 | Percent reduction of treated molluscum lesions from Baseline Visit at the EOS visit. |
| Other | Change From Baseline in the Number of Treated Molluscum Lesions at the EOS Visit. | Baseline to EOS Day 84 | Molluscum Lesions- Change from Baseline visit in the number of treated molluscum lesions at the EOS Day 84 visit |
| Other | Change From Baseline in Quality of Life and Impact of Skin Disease as Measured by CDLQI Assessment | Baseline to EOS Day 84 | Change from Baseline in quality of life and impact of skin disease as measured by CDLQI assessment, Children's Dermatology Life Quality Index (CDLQI)- Composite Score The CDLQI was a 10-item questionnaire completed by subject/parent to assess skin condition over the previous week. From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the CDLQI, a score of 0-3 was assigned using the following scores per response: * 3: Very much (or Prevented School, Question 7 only) * 2: Quite a lot * 1: Only a little * 0: Not at all |
| Other | Spread to Siblings as Measured by Any New Occurrence of Molluscum in Siblings of the Subject. | Baseline to EOS Day 84 | Spread of molluscum to siblings as measured by any new occurrence of molluscum in siblings of the subject. |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | 24 hours | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Measurement of Efficacy - Complete Clearance | Baseline through EOS Day 84 | Complete Clearance of Molluscum Lesions - Completer Population | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Proportion of Subjects Exhibiting a 90% or Greater Reduction of All Treated Molluscum Lesions (Baseline and New) at the EOS Visit. | Baseline to EOS Day 84 | ITT Population | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Percent Reduction of Treated Molluscum Lesions From Baseline at the EOS Visit. | Baseline to EOS Day 84 | ITT Population | percentage change from Baseline | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in the Number of Treated Molluscum Lesions at the EOS Visit. | Baseline to EOS Day 84 | ITT Population | change in wart count | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in Quality of Life and Impact of Skin Disease as Measured by CDLQI Assessment | Baseline to EOS Day 84 | ITT Population | units on a scale change from Baseline | MEAN |
| OTHER_PRE_SPECIFIED | Spread to Siblings as Measured by Any New Occurrence of Molluscum in Siblings of the Subject. | Baseline to EOS Day 84 | ITT Population | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) Pre-treatment / Yes | 0 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) Pre-treatment / No | 16 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 2hr Post Treatment / Yes | 1 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 2hr Post Treatment / No | 15 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 6hr Post Treatment / Yes | 0 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 6hr Post Treatment / No | 16 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 24hr Post Treatment / Yes | 0 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 24hr Post Treatment / No | 16 | Participants | |
| Measurement of Efficacy - Complete Clearance | Exposure Group | Complete Clearance Day 21 | 0 | Participants | |
| Measurement of Efficacy - Complete Clearance | Standard Group | Complete Clearance Day 21 | 3 | Participants |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Exposure Group | 17 | |
| Overall Study | STARTED | Standard Group | 16 | |
| Overall Study | COMPLETED | Exposure Group | 16 | |
| Overall Study | COMPLETED | Standard Group | 16 | |
| Overall Study | NOT COMPLETED | Exposure Group | 1 | |
| Overall Study | NOT COMPLETED | Standard Group | 0 |
Source ClinicalTrials.gov
Adverse events64
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pain | General disorders | Exposure Group | 11 | 17 | |
| other | Pain | General disorders | Standard Group | 8 | 16 | |
| other | Burning Sensation | General disorders | Exposure Group | 1 | 17 | |
| other | Burning Sensation | General disorders | Standard Group | 0 | 16 | |
| other | Pyrexia | General disorders | Exposure Group | 1 | 17 | |
| other | Pyrexia | General disorders | Standard Group | 0 | 16 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Exposure Group | 3 | 17 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Standard Group | 3 | 16 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Exposure Group | 1 | 17 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Standard Group | 2 | 16 |
1 to 10 of 64Source ClinicalTrials.gov
See all 64 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Exposure Group | 0 | 17 |
| Total, all-cause mortality | Standard Group | 0 | 16 |
| Total, other adverse events | Exposure Group | 16 | 17 |
| Total, other adverse events | Standard Group | 13 | 16 |
| Total, serious adverse events | Exposure Group | 0 | 17 |
| Total, serious adverse events | Standard Group | 0 | 16 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33400412 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Exposure Group vs Standard Group: Spread to Siblings as Measured by Any New Occurrence of Molluscum in Siblings of the Subject. | Trial comparisons |
| Exposure Group vs Standard Group: deaths from any cause | Trial comparisons |
| Exposure Group vs Standard Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03186378
GET https://conductscience.org/api/trials/v1/NCT03186378/results?page=2